• Co-Diagnostics held its annual stockholder meeting on Sept. 3, 2026, but no business was conducted because a quorum was not reached.
• No proposals were put to a vote, so no resolutions were adopted or rejected at the meeting.
• The meeting was adjourned to Sept. 24, 2026, for stockholders to vote on the proxy proposals previously disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-041468), on September 04, 2026, and is solely responsible for the information contained therein.